Page last updated: 2024-08-21

clopenthixol and Movement Disorders

clopenthixol has been researched along with Movement Disorders in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19903 (42.86)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's2 (28.57)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bryan, EJ; Kumar, A; Purcell, MA1
Niederhofer, H1
NOECKER, G1
Eerdekens, E; Eerdekens, M; Jacko, M; Turner, M1
Kumar, A; Strech, D1
Achté, KA; Turunen, S1
Poeldinger, W1

Reviews

2 review(s) available for clopenthixol and Movement Disorders

ArticleYear
Zuclopenthixol dihydrochloride for schizophrenia.
    The Cochrane database of systematic reviews, 2017, 11-16, Volume: 11

    Topics: Antipsychotic Agents; Clopenthixol; Humans; Movement Disorders; Randomized Controlled Trials as Topic; Schizophrenia

2017
Zuclopenthixol dihydrochloride for schizophrenia.
    The Cochrane database of systematic reviews, 2005, Oct-19, Issue:4

    Topics: Antipsychotic Agents; Clopenthixol; Humans; Movement Disorders; Randomized Controlled Trials as Topic; Schizophrenia

2005

Trials

1 trial(s) available for clopenthixol and Movement Disorders

ArticleYear
Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics.
    International clinical psychopharmacology, 2004, Volume: 19, Issue:4

    Topics: Adult; Antipsychotic Agents; Clopenthixol; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Flupenthixol; Fluphenazine; Haloperidol; Humans; Injections, Intramuscular; Male; Middle Aged; Movement Disorders; Psychiatric Status Rating Scales; Risperidone; Schizophrenia

2004

Other Studies

4 other study(ies) available for clopenthixol and Movement Disorders

ArticleYear
Tizanidine is not effective treating EPMS.
    Medical hypotheses, 2018, Volume: 116

    Topics: Adolescent; Adult; Basal Ganglia Diseases; Biperiden; Cholinergic Antagonists; Clonidine; Clopenthixol; Female; Humans; Movement Disorders; Schizophrenia; Treatment Outcome

2018
[CLOPENTHIXOL (CIATYL). NEUROLEPTIC EFFECT WITH SPECIAL REFERENCE TO EXTRAPYRAMIDAL SYMPTOMS].
    Medizinische Klinik, 1964, May-08, Volume: 59

    Topics: Antipsychotic Agents; Basal Ganglia Diseases; Clopenthixol; Drug Therapy; Movement Disorders; Schizophrenia; Toxicology; Tranquilizing Agents

1964
The bucco-linguo-masticatory syndrome as a side-effect of neuroleptics therapy.
    The Psychiatric quarterly, 1967, Volume: 41, Issue:2

    Topics: Adult; Aged; Brain Damage, Chronic; Cheek; Chlorpromazine; Chlorprothixene; Clopenthixol; Female; Haloperidol; Humans; Male; Mastication; Middle Aged; Movement Disorders; Parkinson Disease; Perphenazine; Phenothiazines; Reserpine; Thioridazine; Tongue; Tranquilizing Agents

1967
[Comparative clinical-psychiatric experiences with thiaxanthene-derivatives with special consideration of flupenthixol].
    Arzneimittel-Forschung, 1967, Volume: 17, Issue:9

    Topics: Adult; Chlorprothixene; Clopenthixol; Depression; Female; Humans; Male; Middle Aged; Movement Disorders; Oral Manifestations; Paranoid Disorders; Parasympatholytics; Piperazines; Schizophrenia; Tranquilizing Agents; Xanthenes

1967